Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety

Table 3 Odds ratios for sustained viral response at 12 week in multivariate logistic regression for non-cirrhotic, hepatitis c genotype 1 patients treated with 8-week ledipasvir/sofosbuvir therapy

Characteristics	OR (95%CI) for SVR12 (n = 736)	P value
Age 55-65 yr (ref. < 55)	0.92 (0.36-2.34)	0.861
Age > 65 yr (ref. < 55)	0.5 (0.18-1.41)	0.188
Male (ref. female)	0.47 (0.21-1.08)	0.077
African-American (ref. Caucasian)	0.84 (0.11-6.57)	0.868
Hispanic (ref. Caucasian)	2.07 (0.21-20.66)	0.537
Asian/Pacific Islander (ref. Caucasian)	0.98 (0.16-8.28)	0.983
Non-cirrhotic state determined by clinical judgement (ref. Fibrosis Test: biopsy/VCTE/FIBROSPECT)	1.02 (0.48-2.17)	0.962
HCV RNA ≥ 2200000 IU/mL (ref. < 2200000 IU/mL)	0.22 (0.1-0.49)	< 0.001
HCV genotype - subtype 1b (ref. 1a)	2.19 (0.25-19.15)	0.480

HCV: Hepatitis C virus; VCTE: Vibration-controlled transient elastography; SVR: Sustained viral response.